NCT00680225View on ClinicalTrials.gov

Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma

PHASE3CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions
Choroidal Melanoma
Interventions
DRUG

Ranibizumab injection and TTT - ICG based

Intravitreal injection of ranibizumab (0.5mg) once a month for 6 months and transpupillary thermotherapy enhanced with Indocyanine Green (ICG) dye, once or twice starting at 2nd month.

Trial Locations (1)

06518

New England Retina Associates, Hamden

All Listed Sponsors
lead

New England Retina Associates

OTHER

NCT00680225 - Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma | Biotech Hunter | Biotech Hunter